It wasn’t just media news that caused supplement companies to begin searching for hoodia gordonii supplies. Press releases by Phytopharm, a British pharmaceutical company, about researching hoodia and unwanted effects that might be associated with hoodia caused the first stir in the health supplement industry.
Phytopharm has two operating divisions; a place extract division and a pharmaceutical division. In June of 1997, Phytopharm announced that “a naturally occurring appetite suppressant is usually to be developed into a prescription medicine by Phytopharm “.This was to be Phytopharm’s hoodia gordonii product. News of a naturally occurring appetite suppressant sent, not just supplement companies, but those that needed to lose excess weight searching for this “naturally occurring appetite suppressant “.In those days, everyone expected Phytopharm’s hoodia gordonii product to be always a prescription drug though it was consistently referred to by the company as a “natural anti-obesity treatment “.Their collaboration with Pfizer, another pharmaceutical company, to research hoodia and unwanted effects that might be caused by hoodia use only supported the idea that Phytopharm’s hoodia gordonii would have been a prescription drug. Now, since they’ve partnered with Unilever, not just a pharmaceutical company, it is somewhat unclear what Phytopharm’s hoodia gordonii product will be. They do seem focused on the idea that Phytopharm’s hoodia gordonii is going to be superior to products that are now on the market.
Phytopharm’s product development strategy begins in what they call “proof of principle” clinical testing. These tests are made to determine in case a product gets the potential to be safe and effective. Uganda news Proof of principle testing of Phytopharm’s hoodia gordonii product began in March of 2001. News about hoodia and unwanted effects were released after this first phase was completed in December of 2001. This was a naturally occurring substance and there were no unwanted effects associated with its use. After completing the first clinical testing, Phytopharm’s strategy advances to the visit a partner company for “late stage development, sales and marketing “.The partner company for Phytopharm’s hoodia gordonii product is Unilever, manufacturers of food products, dietary supplements and over-the-counter medications. Among their more famous products is “Slim Fast “.Phytopharm continues to be researching and investigating the likelihood or a drug to treat metabolic disorder and hoodia gordonii is the basis for this drug.
Phytopharm attempts to obtain patents for naturally occurring substances. “Phytopica” is really a Phytopharm product for the treatment of dermatitis in dogs and was just released in April of 2006. Phytopharm’s hoodia gordonii product is patented, but they’ve had higher than a little trouble keeping other manufacturers of natural products from selling their very own hoodia products. In May of 2006, they announced that they were aware that other programs were selling hoodia gordonii as an appetite suppressant and they thought that this could be patent infringement. They said that they had contacted the right authorities. The problem is that a naturally occurring product can not be patented. If Phytopharm’s hoodia gordonii product is unique and therefore stronger, safer and better than the hoodia products that are now in the marketplace, then how could there be patent infringement and why would they take into account companies that are selling what they imply are inferior products?
There is no comparison involving the known side ramifications of hoodia and unwanted effects associated with appetite suppressants that have stimulants. Products which contain both hoodia and stimulants could produce a problem. It’s thought that problems with Ephedra arose as a result to be combined with caffeine or other stimulants. The issue was that this might not be proven without endangering human health. Hopefully, Phytopharm’s hoodia gordonii product is going to be stimulant free as are most of the hoodia products that are now on the market.